RT Journal Article
SR Electronic
T1 Brain-first forms of Parkinson′s Disease are over-represented in patients with non-responsive resting tremor
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.23.24310859
DO 10.1101/2024.07.23.24310859
A1 Mendonça, Marcelo
A1 Ferreira, Pedro
A1 Barbosa, Raquel
A1 Da Silva, Joaquim Alves
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310859.abstract
AB Motor subtypes in Parkinson′s Disease (PD) are unstable over time, limiting mechanistic insights and biomarker discovery. We focused on Rest Tremor (RT) as a symptom to test for phenotype stability and link them to specific circuits and disease mechanisms. Using the PPMI cohort data over 5 years we found that RT we found that RT is more stable than common Tremor- Dominant definitions, a stability also seen for therapy response. At time of diagnosis, the population of therapy-resistant RT patients was enriched with a brain-first PD profile as predicted by a-Synuclein origin site and connectome (SOC) model. Resistant-RT patients have lower gastrointestinal and cardiovascular symptoms, lower prevalence of probable REM-Sleep behavior disorder, and higher dopaminergic asymmetry compared to therapy-responsive or no tremor patients. Treating RT as a distinct phenomenon revealed a relative phenotypic stability with treatment response being linked to different patterns of disease progression.Competing Interest StatementMarcelo Mendonca has received, payment, honoraria or other support from Medtronic, Bial, Pharacademy, Evidenze, AbbVie and Stada. RB has received, payment, honoraria or other support from Medtronic and AbbVie. Other authors report no conflict of interest.Funding StatementMM and JAS were supported by grant EurDyscover EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease (EJPRD/0001/2019). MM is supported by the Michael J. Fox Foundation (MJFF-023180) and European Union′s Horizon Programme (Agreement: 101137378, PsyPal project). JAS was supported by the Portuguese Foundation for Technology and Science (FCT) CEEC grant (2020.03118.CEECIND). PF was supported by the Portuguese Foundation for Science and Technology (FCT) through a PhD scholarship (2023.03390.BD) and by the European Union′s Horizon 2020 Research and Innovation Programme through grant H2020-SC1-DTH-2019-875358 (FAITH project).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data. Data used in the preparation of this article were obtained on May, 13, 2023 from the Parkinson′s Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/accessdata- specimens/download-data), RRID:SCR_006431. This analysis used data openly available from PPMI. For up-to-date information on the study, visit http://www.ppmi-info.org. PPMI a public-private partnership is funded by the Michael J. Fox Foundation for Parkinson′s Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson′s, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity TherapeuticsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe PPMI data is part of an open database. Access to PPMI data can be requested at https://www.ppmi-info.org/access-data-specimens/download-data.https://www.ppmi-info.org/access-data-specimens/download-data